• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23475 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2027     Norwegian Medical Products Agency (NOMA) [Wearable cardioverter defibrillator for people with high risk of sudden cardiac arrest: a single technology assessment]
2027     Belgian Health Care Knowledge Centre (KCE) Review of new oncology indications for the use of positron emission tomography (PET-scans) (Study 2024-12)
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [X-ray image of the lung: Can artificial intelligence support the analysis of X-ray images?]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Quality of sleep: Can taking melatonin as a dietary supplement, e.g. in the form of tablets, sprays or soft gums, help to improve sleep?]
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Reinforced foster homes]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP “type 2 diabetes”]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Phonocardiography to rule out coronary heart disease]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Development of a decision aid for carotid revascularization surgery for carotid stenosis]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Pharmacological treatment of polycystic ovary syndrome - health and quality of life in the short and long term]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Interventions for behavioural change in the aim of promoting health and preventing disability in the elderly]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Psychometric properties for instruments used to measure core outcomes for provoked vestibulodynia]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Accuracy of diagnostic algorithms for suspected or elevated risk of ovarian cancer]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Newborn screening for Metachromatic leukodystrophy (MLD)]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Interventions to formal caregivers for increased patient safety]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Digital technology promoting health for children and adolescents]
2025     The Danish Health Technology Council (DHTC) [Assessment of treatment of knee pain]
2025     The Danish Health Technology Council (DHTC) [Assessment of forearm fractures in children]
2025     The Danish Health Technology Council (DHTC) [Assessment of point-of-care tests for use at home for elderly patients]
2025     The Danish Health Technology Council (DHTC) [Assessment of HAL-assisted TUR-BT]
2025     The Danish Health Technology Council (DHTC) [Assessment of SelfBack App for lower back pain]
2025     The Danish Health Technology Council (DHTC) [Assessment of supervised gait training]
2025     The Danish Health Technology Council (DHTC) [Assessment of Merlin Assay for diagnosis of malignant melanoma]
2025     The Danish Health Technology Council (DHTC) [Assessment of percutaneous vertebroplasty (PVP) for compression fractures]
2025     The Danish Health Technology Council (DHTC) [Assessment of endovascular aortic repair (EVAR)]
2025     Swiss Federal Office of Public Health (FOPH) Betahistine or cinnarizine with or without dimenhydrinate for Ménière’s disease/syndrome and symptoms of vestibular vertigo and/or tinnitus
2025     Norwegian Medical Products Agency (NOMA) [Continuous and flash glucose monitoring in patients with type 2 diabetes treated with insulin]
2025     Norwegian Medical Products Agency (NOMA) [Photon-counting detector computed tomography]
2025     Norwegian Medical Products Agency (NOMA) [Volatile gas capture technology. Summary of a health technology assessment by Scottish Health Technologies Group: health technology assessment without submitted documentation]
2025     Norwegian Medical Products Agency (NOMA) [Tumor-treating fields (Optune) for treatment of glioblastoma: a rapid health technology assessment with submitted documentation]
2025     Norwegian Medical Products Agency (NOMA) [Magnetic resonance guided high-intensity focused ultrasound for treatment of essential tremor: single technology assessment]
2025     Norwegian Medical Products Agency (NOMA) [A leadless pacemaker, MicraTM Transcatheter Pacing System, in (sub-groups of) patients with indication for single-chamber ventricular pacing: a single technology re-assessment]
2025     Health Information and Quality Authority (HIQA) Health technology assessment (HTA) of teledermatology for triage of primary care referrals
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of the tiered system of emergency structures in hospitals]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for prostate cancer]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [SSRI / SSNRI: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tricyclic antidepressants: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Agility training: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anticonvulsants: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Strength training: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endurance training: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cognitive behavioural therapy: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cognitive behavioural therapy for insomnia: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mindfulness-based stress reduction: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Consumer health information on lung cancer screening using low-dose computed tomography]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Consumer health information on smoking cessation options]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for implantation of unicondylar sled prosthesis - Update of Project V21-02]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome in knee replacement revision surgery - Update of Project V21-03]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for total knee replacement – Update of Project V21-01]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Scientific evaluation of the relationship between volume of services and quality of treatment outcome for rare diseases]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of cardiac magnetic resonance imaging in coronary heart disease]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Radiofrequency energy treatment for organic erectile dysfunction]
2025     Norwegian Medical Products Agency (NOMA) Intravenous ketamine for treatment-resistant depression
2025     Belgian Health Care Knowledge Centre (KCE) Economic evaluation of whole genome sequencing for children with developmental disorders (Study 2024-09)
2025     Belgian Health Care Knowledge Centre (KCE) Update of prostate cancer screening recommendations (Study 2024-10)
2025     Belgian Health Care Knowledge Centre (KCE) Update of breast cancer screening recommendations (Study 2024-11)
2025     Belgian Health Care Knowledge Centre (KCE) Evaluation of novel blood-based brain biomarkers for mild traumatic brain injuries (Study 2023-11)
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Early detection of graft damage in kidney and heart recipient patients using donor-derived free DNA (dd-cfDNA)]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Branched endovascular prostheses for the treatment of aortic arch pathology]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety and clinical effectiveness of cryoanalgesia in pediatric patients after surgical intervention for pectus excavatum]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness of care models based on the incorporation of psychologists in primary care]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Diagnostic accuracy of ex vivo confocal microscopy during Mohs surgery for basal cell carcinomas]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical practice guideline (CPG) update palliative care]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical practice guideline on deprescribing antidepressants]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Adaptive deep brain stimulation in Parkinson's disease]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Lattice radiotherapy in the curative or palliative treatment of deep, large-volume tumors and metastatic or unresectable disease]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [SSRI/SSNRI: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cimicifuga: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for major liver resection]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Irradiation of the skin with intense pulsed light and radiofrequency for stage I and II hidradenitis suppurativa (Hurley Score)]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vulvodynia (itching and pain in the vulva area): What non-drug treatment options are promising?]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Adhesions in the abdominal cavity: Do other measures help to relieve symptoms instead of surgery?]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Revision of the information materials on colorectal cancer screening]
2025     Swiss Federal Office of Public Health (FOPH) Multigene-expression tests for breast cancer
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Effectiveness and complications of preimplantation genetic testing for aneuploidies (PGT-A) in in vitro fertilisation (IVF)]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Alternative methods to coercive measures]
2025     NIHR Health Technology Assessment programme Protocol for DexEnceph: a randomised controlled trial of dexamethasone therapy in adults with herpes simplex virus encephalitis
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: pharmacokinetics, efficacy and safety of and persistence with treatment with the generic versions of Concerta compared to Concerta]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: psychosocial interventions in youth aged under 18 with attention deficit/hyperactivity disorder (ADHD)]
2024     NIHR Health Technology Assessment programme Assessing long-term effectiveness and cost-effectiveness of statin therapy in the UK: a modelling study using individual participant data sets
2024     NIHR Health and Social Care Delivery Program Early mental health intervention and supported self-care for LGBTQ+ young people in the UK: a mixed-methods study
2024     NIHR Health Technology Assessment programme Collagenase injection versus limited fasciectomy surgery to treat Dupuytren’s contracture in adult patients in the UK: DISC, a non-inferiority RCT and economic evaluation
2024     NIHR Health Technology Assessment programme Point-of-care tests for urinary tract infections to reduce antimicrobial resistance: a systematic review and conceptual economic model
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: environmental impacts in health and social services - what role should health technology assessment agencies play?]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: care management for youth under 18 with attention deficit hyperactivity disorder (ADHD)]
2024     National Institute for Health and Care Excellence (NICE) Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction. NICE interventional procedures guidance 794
2024     National Institute for Health and Care Excellence (NICE) Digital technologies for assessing attention deficit hyperactivity disorder (ADHD). NICE diagnostics guidance 60
2024     National Institute for Health and Care Excellence (NICE) Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices. NICE diagnostics guidance 61
2024     National Institute for Health and Care Excellence (NICE) Belzutifan for treating tumours associated with von Hippel-Lindau disease. NICE technology appraisal guidance 1011
2024     National Institute for Health and Care Excellence (NICE) Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia. NICE technology appraisal guidance 1013
2024     National Institute for Health and Care Excellence (NICE) Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria. NICE technology appraisal guidance 1010
2024     National Institute for Health and Care Excellence (NICE) Avapritinib for treating advanced systemic mastocytosis. NICE technology appraisal guidance 1012
2024     National Institute for Health and Care Excellence (NICE) Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments. NICE technology appraisal guidance 1015
2024     National Institute for Health and Care Excellence (NICE) Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer. NICE technology appraisal guidance 1014
2024     National Institute for Health and Care Excellence (NICE) Elafibranor for previously treated primary biliary cholangitis. NICE technology appraisal guidance 1016
2024     National Institute for Health and Care Excellence (NICE) Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over. NICE technology appraisal guidance 1019
2024     National Institute for Health and Care Excellence (NICE) Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis. NICE technology appraisal guidance 1018
2024     National Institute for Health and Care Excellence (NICE) Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer. NICE technology appraisal guidance 1017
2024     National Institute for Health and Care Excellence (NICE) Eplontersen for treating hereditary transthyretin-related amyloidosis. NICE technology appraisal guidance 1020
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: adjustment of antidepressants for the follow-up of a major depressive disorder or an anxiety disorder]
2024     Haute Autorite de sante (HAS) [Management missing teeth with implant-supported prostheses (complete edentulism or single missing teeth)]